Regulatory approval
Published by the Health Service Executive.
The Republic of Ireland's Health Service Executive (HSE) has approved carboplatin (AUC 6) and weekly packlitaxel (80 mg/m^2) followed by dose dense doxorubicin cyclophosphamide for reimbursement as a treatment option for the neoadjuvant treatment of triple negative breast carcinoma.
This is written in the approval document as:
Neoadjuvant treatment of triple negative breast carcinoma.
Citation
CARBOplatin (AUC 6) and Weekly PACLitaxel 80mg/m2 followed by Dose Dense DOXOrubicin cycloPHOSphamide Therapy-Triple Negative Breast Cancer Therapy, 2022, version number 7, NCCP National SACT Regimen, NCCP, viewed 21/07/2024, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/348.pdfTherapeutic response
Precision oncology relationships for therapeutic response derived from this regulatory approval.| Type | Biomarker(s) | Cancer type | Therapy(ies) | |
|---|---|---|---|---|
| Sensitivity (+) | ER negative, HER2-negative, PR negative | Invasive Breast Carcinoma | Carboplatin, Cyclophosphamide, Doxorubicin, Paclitaxel |